70 Me gusta
- nationalcancerinstituteRepost of @stjuderesearch: Under the leadership of St. Jude computational biologists and pathologists, a national consortium has performed genome-wide analysis of 264 patients with T-lineage acute lymphoblastic leukemia (T-ALL).
While about 90 percent of children with ALL can be cured with chemotherapy and other treatments, a significant percentage, including those with T-ALL, relapse. The new study revealed 106 “driver genes,” whose mutations trigger T-ALL. Significantly, half these genes were unknown before the study.
The new detailed knowledge of the genomic landscape of T-ALL gives researchers a view of such “constellations” of mutations, improving our understanding of the subtypes of the cancer and how best to treat them.
The collaborative study included data from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project, the Children’s Oncology Group and the National Cancer Institute’s Therapeutically Applicable Research to Generate Effective Treatments initiative. The study constitutes the largest number of T-ALL patients ever studied in such genetic detail.
Photo by St. Jude Biomedical Communications.
#stjuderesearch #stjude #childhoodcancer #cancer #pedonc #oncology
#cancerawareness #cancerresearch #cancersurvival #SurvOnc
#science #research #Memphis #hospital #childrenshospital #childhoodcancerawareness
#leukemia #computationalbiology #pathology #genome #genes #NatureGenetics #ChildrensOncologyGroup @wustl_official @nationalcancerinstitute - lanaclayWhere will this data be published?
- nationalcancerinstituteThe study appeared in Nature Genetics on July 3. https://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3909.html